[1] T. Ito, M.J. Young, R. Li, S. Jain, A. Wernitznig, J.M. Krill-Burger, C.T. Lemke, D. Monducci, D.J. Rodriguez, L. Chang, S. Dutta, D. Pal, B.R. Paolella, M.V. Rothberg, D.E. Root, C.M. Johannessen, L. Parida, G. Getz, F. Vazquez, J.G. Doench, M. Zamanighomi, W.R. Sellers, Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers, Nat Genet. 53 (2021) 1664–1672. doi:10.1038/s41588-021-00967-z.
[2] J.M. García-Martínez, S. Wang, C. Weishaeupl, A. Wernitznig, P. Chetta, C. Pinto, J. Ho, D. Dutcher, P.N. Gorman, R. Kroe-Barrett, J. Rinnenthal, C. Giragossian, M.A. Impagnatiello, I. Tirapu, F. Hilberg, N. Kraut, M. Pearson, K.P. Kuenkele, Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist, Mol Cancer Ther. 20 (2021) 96–108. doi:10.1158/1535-7163.MCT-20-0253.
[3] D.J. Lamb, A. Rust, A. Rudisch, T. Glüxam, N. Harrer, H. Machat, I. Christ, F. Colbatzky, A. Wernitznig, A. Osswald, W. Sommergruber, Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells, Oncotarget. 11 (2020) 1257–1272. doi:10.18632/oncotarget.27545.
[4] D. Wernitznig, S.M. Meier-Menches, K. Cseh, S. Theiner, D. Wenisch, A. Schweikert, M.A. Jakupec, G. Koellensperger, A. Wernitznig, W. Sommergruber, B.K. Keppler, Plecstatin-1 induces an immunogenic cell death signature in colorectal tumour spheroids, Metallomics. 12 (2020) 2121–2133. doi:10.1039/d0mt00227e.
[5] D. Wernitznig, K. Kiakos, G. Del Favero, N. Harrer, H. Machat, A. Osswald, M.A. Jakupec, A. Wernitznig, W. Sommergruber, B.K. Keppler, First-in-class ruthenium anticancer drug (kp1339/it-139) induces an immunogenic cell death signature in colorectal spheroids in vitro, Metallomics. (2019) –. doi:10.1039/C9MT00051H.
[6] S. Lieb, S. Blaha-Ostermann, E. Kamper, J. Rippka, C. Schwarz, K. Ehrenhofer-Wolfer, A. Schlattl, A. Wernitznig, J.J. Lipp, K. Nagasaka, P. vanDerLelij, G. Bader, M. Koi, A. Goel, R.A. Neumuller, J.M. Peters, N. Kraut, M.A. Pearson, M. Petronczki, S. Wohrle, Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells, Elife. 8 (2019). doi:10.7554/eLife.43333.
[7] M. Streit, S. Gratzl, H. Stitz, A. Wernitznig, T. Zichner, C. Haslinger, Ordino: a visual cancer analysis tool for ranking and exploring genes, cell lines and tissue samples, Bioinformatics. (2019). doi:10.1093/bioinformatics/btz009.
[8] T. Zoranovic, J. Manent, L. Willoughby, R. Matos de Simoes, J.E. La Marca, S. Golenkina, X. Cuiping, S. Gruber, B. Angjeli, E.E. Kanitz, S.J.F. Cronin, G.G. Neely, A. Wernitznig, P.O. Humbert, K.J. Simpson, C.S. Mitsiades, H.E. Richardson, J.M. Penninger, A genome-wide drosophila epithelial tumorigenesis screen identifies tetraspanin 29Fb as an evolutionarily conserved suppressor of ras-driven cancer, PLOS Genetics. 14 (2018) 1–36. doi:10.1371/journal.pgen.1007688.
[9] M.P. Sanderson, M.H. Hofmann, P. Garin-Chesa, N. Schweifer, A. Wernitznig, S. Fischer, A. Jeschko, R. Meyer, J. Moll, T. Pecina, H. Arnhof, U. Weyer-Czernilofsky, S.K. Zahn, G.R. Adolf, N. Kraut, The IGF1R/INSR inhibitor BI 885578 selectively inhibits growth of IGF2-overexpressing colorectal cancer tumors and potentiates the efficacy of anti-VEGF therapy, Mol. Cancer Ther. 16 (2017) 2223–2233. doi:10.1158/1535-7163.MCT-17-0336.
[10] C. Unger, N. Kramer, D. Unterleuthner, M. Scherzer, A. Burian, A. Rudisch, M. Stadler, M. Schlederer, D. Lenhardt, A. Riedl, S. Walter, A. Wernitznig, L. Kenner, M. Hengstschlager, J. Schuler, W. Sommergruber, H. Dolznig, Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms, Oncogene. 36 (2017) 5341–5355. doi:10.1038/onc.2017.116.
[11] A. Rudisch, M.R. Dewhurst, L.G. Horga, N. Kramer, N. Harrer, M. Dong, H. van der Kuip, A. Wernitznig, A. Bernthaler, H. Dolznig, W. Sommergruber, High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts, PLoS ONE. 10 (2015) e0124283.
[12] D. Rudolph, M.A. Impagnatiello, C. Blaukopf, C. Sommer, D.W. Gerlich, M. Roth, U. Tontsch-Grunt, A. Wernitznig, F. Savarese, M.H. Hofmann, C. Albrecht, L. Geiselmann, M. Reschke, P. Garin-Chesa, J. Zuber, J. Moll, G.R. Adolf, N. Kraut, Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia, J. Pharmacol. Exp. Ther. 352 (2015) 579–589.
[13] S. Glatt, D. Halbauer, S. Heindl, A. Wernitznig, D. Kozina, K.C. Su, C. Puri, P. Garin-Chesa, W. Sommergruber, hGPR87 contributes to viability of human tumor cells, Int. J. Cancer. 122 (2008) 2008–2016.
[14] K. Aigner, B. Dampier, L. Descovich, M. Mikula, A. Sultan, M. Schreiber, W. Mikulits, T. Brabletz, D. Strand, P. Obrist, W. Sommergruber, N. Schweifer, A. Wernitznig, H. Beug, R. Foisner, A. Eger, The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity, Oncogene. 26 (2007) 6979–6988.
[15] K. Aigner, L. Descovich, M. Mikula, A. Sultan, B. Dampier, S. Bonne, F. van Roy, W. Mikulits, M. Schreiber, T. Brabletz, W. Sommergruber, N. Schweifer, A. Wernitznig, H. Beug, R. Foisner, A. Eger, The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression, FEBS Lett. 581 (2007) 1617–1624.
[16] V. Weber, A. Wernitznig, G. Hager, M. Harata, P. Frank, U. Wintersberger, Purification and nucleic-acid-binding properties of a Saccharomyces cerevisiae protein involved in the control of ploidy, Eur. J. Biochem. 249 (1997) 309–317.
Copyright © 2017-2021 Andreas Wernitznig. All rights reserved.